Compare · BTSG vs WGS
BTSG vs WGS
Side-by-side comparison of BrightSpring Health Services Inc. (BTSG) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTSG and WGS operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- BTSG is the larger of the two at $13.36B, about 7.2x WGS ($1.86B).
- BTSG has been more active in the news (6 items in the past 4 weeks vs 5 for WGS).
- BTSG has more recent analyst coverage (23 ratings vs 8 for WGS).
- Company
- BrightSpring Health Services Inc.
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $13.36B
- $1.86B
- 1M return
- +5.43%
- -
- 1Y return
- +102.50%
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 23
- 8
Latest BTSG
- New insider Hopper Jeffrey A. claimed ownership of 42,295 shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by BrightSpring Health Services Inc.
- SEC Form 10-Q filed by BrightSpring Health Services Inc.
- BrightSpring Health Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BrightSpring Health Services, Inc. Reports Third Quarter 2026 Financial Results and Increases Full Year 2026 Guidance
- SEC Form 4 filed by BrightSpring Health Services Inc.
- BrightSpring Health Services, Inc. to Announce Third Quarter 2026 Financial Results on October 30, 2026
- President, PharMerica Greenwell Scott A. exercised 11,973 shares at a strike of $22.27 and sold $874,383 worth of shares (15,099 units at $57.91), decreasing direct ownership by 9% to 31,246 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by BrightSpring Health Services Inc.
- SEC Form 10-Q filed by BrightSpring Health Services Inc.
Latest WGS
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
- GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
- GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
- GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)